latest news releases from the newsroom
Boliden: Recycling energy from Ronnskar's processes boosts Skelleftea Kraft's electricity stocks
STOCKHOLM, Sweden, Nov. 4, 2004 (PRIMEZONE) -- Boliden (TSE:BLS) and Skelleftea Kraft are launching a partnership project called ECOEL. A restructuring of the Ronnskar smelter's energy systems will increase the extent to which waste heat from the smelter can be converted into electricity. The increase is estimated at approximately 30 GWh per year, corresponding to the annual consumption of 1,000 average houses. Steam is delivered to Skelleftea Kraft and converted into electricity.
Pure H2O Bio-Technologies, Inc.
Pure H20 Bio-Technologies, Inc. Committed to Combat Waterborne Diseases
BOCA RATON, Fla., Nov. 4, 2004 (PRIMEZONE) -- Pure H20 Bio-Technologies, Inc. (Pink Sheets:PHBT) announced today its commitment to combat waterborne diseases. At least 12% of United States households treat their drinking water in some fashion and industry analysts expect this number to increase to 40% by the year 2010. In an earlier market assessment, health officials estimate that 900,000 people each year become infected with waterborne disease and the General Accounting Office estimates that 66% of Safe Drinking Water Act violations are not reported. These findings along with the evolution of chlorine-resistant organisms suggest that the demand for high purity water by end users will continue to increase.
Song Networks Holding
Song Networks reaches deal with Visma Advantage AS
STOCKHOLM, Sweden, Nov. 04, 2004 (PRIMEZONE) -- Song Networks Holding AB's (Stockholm:SONW) Norwegian subsidiary Song Networks AS has reached a deal with Visma Advantage AS for the provision of fixed telephony and Internet access to Visma Advantage's customers. Annually, the deal is worth minimum NOK 20 million and will run until further notice.
Antisoma Telomere Targeting Agent Stops Tumour Growth In Prostate Cancer Model
LONDON, Nov. 4, 2004 (PRIMEZONE) -- Cancer drug developer Antisoma today presents new data showing that one of its telomere targeting agents (TTAs) rapidly blocks prostate tumour growth in a human xenograft model. While in untreated control animals tumours grew to lethal size within 10 days, animals given the TTA experienced a halt in tumour growth at around day 7 and survived to the experiment's end on day 25. These findings extend the range of cancers shown to be susceptible to Antisoma's TTAs and demonstrate that the drugs have profound effects on tumour growth even when used as a sole treatment.